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Abstract
A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for
the impact of O6-methly-guanly-methyl-transferase (MGMT)-promoter methylation as well as isocitrate dehydrogenase
(IDH)1-mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group
with methylated MGMT-promoter as compared to patients without that methylation. IDH-1 mutations were
significantly associated with increased overall survival.
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Introduction
Over recent years, the search for outcome factors in
patients with glioblastomas (GBM) has identified at least
two candidates that have shown to be prognostic for
progression-free and overall survival or predictive for
response to a particular therapeutic modality, that is
alkylating chemotherapy, in patients with high-grade
gliomas. The O6-methylguanine-DNA-methyltransferase
(MGMT) gene encodes MGMT,ap r o t e i nw i t hD N A
repair activity, which removes alkyl groups from several
residues, of which the O6-position of guanine might be
most relevant for the action of an extensively used che-
motherapeutic drug, temozolomide, by an irreversible
transfer of the alkyl group to a cystein residue at it’s
active side [1,2]. The MGMT expression level and its
activity varies widely between different tissues, cell
types, and in particular, between different tumors [3,4].
It has been shown that glial brain tumors are character-
ized by a low expression of MGMT, however, the activ-
ity of MGMT is commonly increased in relation to
surrounding normal tissue [4,5].
MGMT-activity is partly mediated through methyla-
tion of the MGMT promoter region; this epigenetic
mechanism contributing to a loss of MGMT-expression
has been described by Esteller et al. [6]. The epigeneti-
cally mediated silencing of the MGMT gene in GBM
has been shown to correlate with an increased survival:
Some studies have shown significant correlation with
MGMT-promoter methylation and outcome to alkylat-
ing chemotherapeutic substances such as temozolomide
(TMZ) [7]. Moreover, a correlation with outcome inde-
pendently of treatment choice, i.e. chemotherapy or
radiotherapy, has been postulated by some authors [7,8].
However, until now, most reports on the prognostic
value of MGMT-promoter methylation have answered
this question in a retrospective manner. Additionally,
several methods of MGMT-promoter methylation con-
f i r m a t i o nh a v eb e e nu s e dw i t h i nt h ed i f f e r e n ts t u d i e s ,
and comparative analyses have shown substantial het-
erogeneity in results after MGMT-testing. In the litera-
ture, some authors have reported that MGMT promoter
methylation might not be correlated with outcome,
either after treatment with radiotherapy, or with alkylat-
ing chemotherapeutic substances [9,10].
Only recently, mutations of the IDH1 gene encoding
cytosolic NADP+-dependent isocitrate dehydrogenase
have been show to correlate with outcome in patients
with malignant gliomas [11,12]. It has been proposed
that IDH1 mutations can be used to distinguish primary
from secondary GBM, since IDH1 mutations are
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as well as with secondary GBM, whereas primary GBM
rarely show IDH1 mutations.
We have treated a large group of patients with pri-
mary GBM with radiotherapy and chemotherapy with
temozolomide. To determine the prognostic value of
MGMT-promoter methylation and IDH1 mutational sta-
tus, we analyzed both markers in a homogenous group
of 160 patients with primary GBM treated with radia-
tion and TMZ and correlated results with outcome.
Materials and methods
Patient population
Between 1999 and 2007, 160 consecutive patients with
primary, histologically confirmed GBM were treated
with radiation and temozolomide as reported previously
[13,14].
After neurosurgical resection, which was complete in
51 patients and subtotal in 66 patients, patients were
treated with 3D-conformal radiation therapy based on
CT- and MRI-based treatment planning. The median
age of the patients included was 56 years at primary
diagnosis (range 20-76 months). Patients’ characteristics
are shown in table 1.
Am e d i a nd o s eo f6 0G yi n2G ys i n g l ef r a c t i o n sw a s
applied. All patients were treated with concomitant
TMZ, and adjuvant TMZ was given in 34 patients. At
this time, a phase II trial evaluation radiation and che-
motherapy with TMZ at a dose of 50 mg/m
2 without
adjuvant TMZ was performed in our institution, there-
fore 124 patients had been treated according to this
regimen, and 36 patients received TMZ according to the
Stupp regimen [13,15,16]. A detailed report on patient
and treatment characteristics has been published pre-
viously [14].
Molecular analyses and immunohistochemistry
Tumor tissue for molecular analysis of MGMT-promo-
ter methylation was available from 127 out of 160
patients (80%). MGMT status was determined using
methylation-specific polymerase chain reaction [6].
Details are described elsewhere [17].
To determine the IDH1-mutational status we used
either immunohistochemistry with an antibody specifically
binding the R132H mutational variant of IDH1 (n = 125)
or direct sequencing (n = 15). To determine the IDH1 sta-
tus by immunohistochemistry, sections were cut to 4 μm,
dried at 80°C for 15 min and further processed on a Ven-
tana BenchMark XT immunostainer (Ventana Medical
Systems, Tucson, AZ, USA). After 60 min pretreatment
with cell conditioner 2 (pH 6) the slides were incubated
with 1:30 diluted H09 antibody (Dianova, Hamburg, Ger-
many) at 37°C for 32 min. Antibody incubation was fol-
lowed by Ventana standard signal amplification,
UltraWash, counterstaining with one drop of hematoxylin
for 4 min and one drop of bluing reagent for 4 min. For
chromogenic detection UltraViewTMUniversal DAB
Detection Kit (Ventana) was used. Slides were removed
from the immunostainer and mounted. A strong cytoplas-
mic immunoreaction product was scored positive. A weak
diffuse staining and staining of macrophages were not
scored positive. Figure 1 depicts an example of the immu-
nohistochemistry as well as sequencing results.
Statistical Analysis
All patients were seen for regular follow-up and clinical
data was collected in the institutions’s database. For the
present analysis, we correlated status of MGMT-promo-
ter methylation as well as IDH-1 mutational status with
patients’ characteristics and outcome.
Table 1 Patients’ characteristics of 160 patients treated
with radiation and temozolomide for primary
glioblastoma
Characteristic N (%)
Age - years
median 56
range 20-76
Age - no. (%)
< 50 38 (24)
≥ 50 122 (76)
Sex - number (%)
female 66 (41)
male 94 (59)
Karnofsky Performance Score
≥ 70 115 (72)
< 70 45 (28)
Extent of surgery - no. (%)
biopsy 43 (27)
complete resection 51 (32)
partial resection 66 (41)
RPA/EORTC-Classification
III 33 (21)
IV 90 (56)
V 37 (23)
Time from diagnosis to RT - days
median 24
range 7-98
Corticosteroid therapy - no. (%)
yes 113 (71)
no 47 (29)
Anti-seizure medication - no. (%)
yes 75 (47)
no 85 (53)
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primary diagnosis until death or last observation during
follow up (censored data). Progression-free survival
(PFS) was determined from the time of the beginning of
radiotherapy and chemotherapy until tumor progression
or to last observation or death if none occurred (cen-
sored data). OS and PFS were calculated using the
Kaplan-Meier-Method. Survival curves for prognostic
factors were compared using a two-sided log rank test.
All statistical analyses were performed using the Statis-
tica 6.1 software (Statsoft, Tulsa, OK, USA).
Results
Molecular analyses: MGMT Promoter Methylation
Of the 127 patients analyzed, the MGMT-promoter was
methylated in 43 patients (34%) and was unmethylated
in 84 patients (66%).
MGMT-promoter methylation did not correlate with
overall survival (OS; p = 0.18 (Figure 2A)). Additionally
progression-free-survival was not influenced by MGMT-
promoter methylation status (p = 0.93; Figure 2B).
Looking at subgroups, we analyzed the impact of
MGMT- promoter methylation on OS and PFS in
patients ≤ 60 yrs. (n = 85; 53%) and > 60 yrs. (n = 75;
47%). In the younger age group MGMT-promoter
methylation did not influence OS (p = 0.93) or PFS (p =
0.69). However, in older patients, MGMT-promoter
methylation was associated with a significant increase in
OS (p = 0.02), however PFS was comparable (p = 0.11).
Molecular analyses and immunohistochemistry: IDH1
F o u ro ft h e1 4 0p a t i e n t s( 3 % )s h o w e da nI D H 1m u t a -
tion; all mutations were of the R132H variant. The 4
patients with a positive IDH1 mutations status showed
significantly longer OS (p = 0.002; Figure 3A), but unal-
tered PFS (p = 0.25) than patients with wildtype IDH1.
Discussion
In the present analysis we evaluated the impact of
MGMT-promother methylation as well as IDH1-muta-
tional status on outcome in 160 patients with GBM
treated with radiation and temozolomide. IDH1 muta-
tions occur in approximately 60 - 80% of diffusely infil-
trating gliomas of the WHO grades II and III and in
secondary GBM but only in around 5% of primary GBM
[11,18-22]. In our series we identified in 4 of 140
patients (3%) IDH-1 mutations. Currently, it remains
unclear if at least some of the patients with clinically
defined primary GBM and IDH1 mutations may actually
have suffered from secondary GBM that rapidly pro-
gressed from less malignant precursor lesions that
escaped diagnosis [23]. In summary, IDH1 is a sufficient
marker that allows a better separation of primary GBM
from other malignant astrocytomas than any other mar-
ker and will help to define more accurately this tumor
entity in upcoming studies. The low number of primary
GBM exhibiting IDH1 mutations in our series indicates
that our sample set consists indeed predominately of
these tumors. IDH1mutations in GBM were found in
general in younger patients and were associated with a
better prognosis [22-24]. This has been confirmed in the
present study, showing that IDH1 mutational status,
although only positive in few patients, is associated with
younger age and lower survival times than in the group
of patients with wildtype IDH1. Therefore, the pattern
of IDH1 mutations confirm that the present group of
Figure 1 GBM sample with an IDH1 R132H mutation demonstrated by IHC and sequencing.
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with respect to histological clasification.
In contrast to most studies, MGMT-promoter
methylation was not associated with an increase in OS
or PFS; both endpoints were comparable in patients
with active MGMT or with MGMT silencing. The only
subgroup of patients showing a significant impact of
MGMT-promoter methylation on survival were
patients older than 60 years, where MGMT-promoter
methylation was associated with an increase in OS.
This is in contrary to the results published by Stupp
and colleagues [7,15]. Therefore, the strong impact on
MGMT-promoter methylation might not hold true for
all age groups of patients with GBM. The EORTC
26981/22981/NCIC CE.3 study by Stupp et al.
determining the role for chemoradiation with temozo-
lomide has shown MGMT-promoter methylation to be
strongly associated with an improved outcome [7,15].
In contrast, other studies in anaplastic gliomas have
shown that MGMT-methylation status dose not only
influence outcome after alkylkating chemotherapies
but also radiotherapy and may therefore be prognostic
rather than predictive. This is reported by numerous
other studies [8]. However, controversial results have
also been published in groups of GBM patients, in
which MGMT-status is not associated with differences
in outcome: Costa et al. reports on 90 GBM-patients
treated with temozolomide-based chemoradiation
where MGMT promoter methylation was not asso-
ciated with increased outcome [10]. Park et al. pub-
lished 48 patients treated with alkylating chemotherapy
and could not confirm a significant impact of methyla-
tion status of MGMT gene promoter [9]. Many argu-
ments may be brought forward to explain these
differing clinical data, including the various methods of
measurement of MGMT-activity sometimes showing
discrepant results, differences between frozen or paraf-
fin embedded tissues. Additionally, when analyzing dif-
ferent chemotherapeutic combinations, substances
such as cisplatinum might inactivate or attenuate
MGMT-status thus influencing the clinical outcome
when combined with alkylating chemotherapies. An
important differential explanation is the variation of
the treatment in our cohort as compared to the pub-
lished data [7,16,17,25,26] with a lower exposure of
our patients to alkylating chemotherapy both in the
concomitant phase (50 mg in 78% and 75 mg in only
22%) as well as in the maintenance phase (no adjuvant
p=0.002
Figure 3 IDH-1 mutational status did influcence overall survival in
160 patients treated with radiation and temozolomide (p = 0.002).
AB
p=0.18 p=0.93
Figure 2 Correlation of overall survival (A) and progression-free survival (B) with MGMT-promotor methylation. For both endpoints,
MGMT-activity did not significantly influence outcome.
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patients). However, inspite of this difference, outcome
between the two dosing groups of temozolomide was
identical, therefore counteracting this argument.
In conclusion, controversial results exist on the impact
of MGMT-promoter methylation status in patients with
GBM, and further studies will hopefully further clarify
these differences. At this time, in spite of the strong evi-
d e n c ef o rah i g hi m p a c to fMGMT-promoter methyla-
tion, differentiating treatment strategies based on
MGMT-promoter methylation status should therefore
be applied within the framework of clinical studies only.
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